Hemolytic anemia resident survival guide: Difference between revisions

Jump to navigation Jump to search
Line 98: Line 98:
*Treatment plan is summarized in the algorithm below based on the 2017 guidelines published by the British Society of Hematology and<ref name="pmid31597833">{{cite journal| author=Kamesaki T| title=[Progress in diagnosis and treatment of autoimmune hemolytic anemia]. | journal=Rinsho Ketsueki | year= 2019 | volume= 60 | issue= 9 | pages= 1100-1107 | pmid=31597833 | doi=10.11406/rinketsu.60.1100 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31597833  }} </ref> and the 2020 recommendations by the First International Consensus Group.<ref name="pmid31839434">{{cite journal| author=Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA | display-authors=etal| title=Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. | journal=Blood Rev | year= 2020 | volume= 41 | issue=  | pages= 100648 | pmid=31839434 | doi=10.1016/j.blre.2019.100648 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31839434  }} </ref>
*Treatment plan is summarized in the algorithm below based on the 2017 guidelines published by the British Society of Hematology and<ref name="pmid31597833">{{cite journal| author=Kamesaki T| title=[Progress in diagnosis and treatment of autoimmune hemolytic anemia]. | journal=Rinsho Ketsueki | year= 2019 | volume= 60 | issue= 9 | pages= 1100-1107 | pmid=31597833 | doi=10.11406/rinketsu.60.1100 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31597833  }} </ref> and the 2020 recommendations by the First International Consensus Group.<ref name="pmid31839434">{{cite journal| author=Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA | display-authors=etal| title=Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. | journal=Blood Rev | year= 2020 | volume= 41 | issue=  | pages= 100648 | pmid=31839434 | doi=10.1016/j.blre.2019.100648 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31839434  }} </ref>
{{familytree/start |summary=Treatment of hemolytic anemia.}}
{{familytree/start |summary=Treatment of hemolytic anemia.}}
{{familytree | | | | | | | | | | | | | | A01 | |A01= History <br>
{{familytree | | | | | | | | | | | | | | A01 | |A01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''History''' <br>
*Fatigue
*Fatigue
*Dyspnea
*Dyspnea
*Lightheadedness<br>
*Lightheadedness<br>
Physical examination
'''Physical examination'''
*Pallor
*Pallor
*Icterus
*Icterus
*Cold, clammy skin}}
*Cold, clammy skin}}
{{familytree | | | | | | | | | | | | | | |!| | |}}
{{familytree | | | | | | | | | | | | | | |!| | |}}
{{familytree | | | | | | | | | | | | | | B01 | |B01=B01}}
{{familytree | | | | | | | | | | | | | | B01 | |B01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initial investigations''' <br>
*[[Complete blood count]]
*[[Peripheral smear]]
*[[Reticulocyte count]]
*[[Complete urine examination]]
*[[Unconjugated bilirubin]]
*[[Lactate dehydrogenase]] </div>}}
{{familytree | | | | | | | | | | | | | | |!| | |}}
{{familytree | | | | | | | | | | | | | | C01 | |C01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Confirm hemolysis''' <br>
*Low [[hemoglobin]]
*Elevated [[lactate dehydrogenase]]
*Low [[haptoglobin]]
*High [[unconjugated bilirubin]]
*[[Reticulocytosis]]
*[[Hemoglobinuria]] </div>}}
{{familytree | | | | | | | | | | | | | | |!| | |}}
{{familytree | | | | | | | | | | | | | | D01 | |D01=<div style="float: left; text-align: center; width: 20em; padding:1em;">'''Peripheral blood smear findings''' </div>}}
{{familytree | | | | | | | | | | | | | | |!| | |}}
{{familytree | | | | | | | | | | |,|-|-|-|+|-|-|-|.| | | |}}
{{familytree | | | | | | | | | | E01 | | E02 | | E03 |E01=<div style="float: left; text-align: center; width: 20em; padding:1em;">[[Shistocytes]]</div>|E02=<div style="float: left; text-align: center; width: 20em; padding:1em;">[[Spherocytes]]</div>|E03=<div style="float: left; text-align: center; width: 20em; padding:1em;">Bite cells </div>}}
{{familytree | | | | | | | | | | |!| | | |!| | | |!| | |}}
{{familytree | | | | | | | | | | F01 | | F02 | | F03 |F01=<div style="float: left; text-align: center; width: 20em; padding:1em;">'''[[Microangiopathic hemolytic anemia]]'''</div>|F02=<div style="float: left; text-align: center; width: 20em; padding:1em;">'''[[Coomb's test|Direct antibody test]]'''</div>|F03=<div style="float: left; text-align: left; width: 20em; padding:1em;">Oxidative stress like<br>
* [[G6PD deficiency]]
* Consumption of certain foods like fava beans
* Oxidative drugs such as [[quinidine]], [[sulfa drugs]] etc</div>}}
{{familytree | | | | | | | | | | |!| | | |!| | | |!| | | }}
{{familytree | | | | | | | | | | G01 | | |!| | | G02 | |G01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Further investigations''' <br>
* [[PT]]/[[PTT]]
* [[Renal function tests]]
* [[Blood pressure]]
* [[Liver function tests]]
* [[ADAMTS13]] level
* Positive [[Shiga toxin]]/[[EHEC]] test</div>|G02=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Treatment of acute attacks'''<br>
* [[Blood transfusion]]
* [[Hemodialysis]]
'''Long term measures'''<br>
* Avoidance of trigger foods and drugs
* [[Splenectomy]]- spleen is the site of destruction of RBCs
* Avoid [[aspirin]] as it reduces the lifecycle of RBCs
* Vaccination against common trigger infections such as [[Hepatitis A]]& [[Hepatitis B|B]] </div>}}
{{familytree | | | | | | | | | | |!|,|-|-|+|-|-|.| | | | |}}
{{familytree | | | | | | | | | | |!| H01 | | | H02 | |H01=<div style="float: left; text-align: Center; width: 10em; padding:1em;">'''Negative'''<br>
Hereditary spherocytosis</div>|H02=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Positive'''<br>
* Autoantibodies
* Alloimmunization
* Drug-induced
Treatment of drug induced hemolytic anemia includes removal of offending agent</div>}}
{{familytree | | | | | | | | | | |!| |!| | |,|-|^|-|.|}}
{{familytree | | | | | | | | | | |!| |!| | |!| | | I01 |I01=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Alloimmunisation treatment'''<br>
Causes: ABO incompatible or Rh incompatible transfusion
* Stop transfusion immediately
* Fluid replacement
* Monitor vital signs
* [[Vasoconstrictor|Pressor]] support
* [[Hemodialysis]]
* If DIC occurs then treatment with [[fresh frozen plasma]], [[platelet transfusion]] or [[cryoprecipitate]]</div>}}


== Do's ==
== Do's ==

Revision as of 19:21, 4 August 2020

Hemolytic anemia
Resident Survival Guide
Overview
Causes
FIRE
Diagnosis
Treatment
Do's
Don'ts


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Overview

Causes

Life threatening causes

Other causes

For a complete list of hemolytic anemia causes click here

Diagnosis

The approach to diagnosis of hemolytic anemia is based on a step-wise testing strategy. Below is an algorithm summarising the identification and laboratory diagnosis of hemolytic anemia.

 
 
 
 
 
 
 
 
 
 
 
 
Characterize the symptoms:
Weakness
Shortness of breath
Jaundice
Lethargy
Chest pain and reduced exercise tolerance
Pica
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:
Tachypnea
❑ Cold and clammy skin
Hypotension
❑ HEENT signs:


❑ Cardiovascular exam:


❑ Abdominal exam:


❑ Skin exam:

  • Pallor of nail beds, palmar creases
  • Bronze skin colour in case of repeated transfusions
  • Leg ulcers

Fever and neurological signs are seen in TTP
Hemoglobinuria in some cases
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial workup for hemolysis:
❑ Indirect bilirubin
❑ serum haptoglobin
Lactate dehydrogenase level
Reticulocyte count
Urinalysis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No laboratory evidence of hemolysis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Degmacytes
 
Normal cell morphology
 
Spherocytes
 
Elliptocytes
 
Shistocytes
 
Sickle shaped cells
 
Hypochromic, microcytic cells
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G6PD deficiency
 
Family history
❑ Drug history
❑ Recent infections
 
 
 
 
 
 
 
 
Sickle cell disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H/o exercise, exertion, trauma or surgery?
 
 
 
 
 
Beta thalassemia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Negative
 
Positive
 
No
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD55/59
 
❑ Drug induced hemolytic anemia
❑ Autoimmune disease
 
❑Exercise induced hemolysis
Prosthetic heart valve
❑Severe aortic stenosis
 
Microangiopathic hemolytic anemia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive
 
 
 
Negative
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pre-eclampsia and eclampsia
 
Recent diarrhea
 
 
Decreased ADAMTS13 activity
 
 
 
 
 
Paroxysmal nocturnal hemoglobinuria
 
 
 
Hereditary spherocytosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HELLP syndrome
 
Hemolytic uremic syndrome
 
 
Thrombotic thrombocytopenic purpura
 

Treatment

  • The treatment of hemolytic anemia depends on the cause of anemia.[5][6][7]
  • Treatment plan is summarized in the algorithm below based on the 2017 guidelines published by the British Society of Hematology and[8] and the 2020 recommendations by the First International Consensus Group.[9]

Do's

Don'ts

References

  1. Phillips J, Henderson AC (2018). "Hemolytic Anemia: Evaluation and Differential Diagnosis". Am Fam Physician. 98 (6): 354–361. PMID 30215915.
  2. Renard D, Rosselet A (2017). "Drug-induced hemolytic anemia: Pharmacological aspects". Transfus Clin Biol. 24 (3): 110–114. doi:10.1016/j.tracli.2017.05.013. PMID 28648734.
  3. Morishita E (2015). "[Diagnosis and treatment of microangiopathic hemolytic anemia]". Rinsho Ketsueki. 56 (7): 795–806. doi:10.11406/rinketsu.56.795. PMID 26251142.
  4. Barcellini W, Bianchi P, Fermo E, Imperiali FG, Marcello AP, Vercellati C; et al. (2011). "Hereditary red cell membrane defects: diagnostic and clinical aspects". Blood Transfus. 9 (3): 274–7. doi:10.2450/2011.0086-10. PMC 3136593. PMID 21251470.
  5. Matsumoto M, Fujimura Y, Wada H, Kokame K, Miyakawa Y, Ueda Y; et al. (2017). "Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan". Int J Hematol. 106 (1): 3–15. doi:10.1007/s12185-017-2264-7. PMID 28550351.
  6. Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J; et al. (2019). "Hemolytic uremic syndrome in a developing country: Consensus guidelines". Pediatr Nephrol. 34 (8): 1465–1482. doi:10.1007/s00467-019-04233-7. PMID 30989342.
  7. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH; et al. (2014). "Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members". JAMA. 312 (10): 1033–48. doi:10.1001/jama.2014.10517. PMID 25203083.
  8. Kamesaki T (2019). "[Progress in diagnosis and treatment of autoimmune hemolytic anemia]". Rinsho Ketsueki. 60 (9): 1100–1107. doi:10.11406/rinketsu.60.1100. PMID 31597833.
  9. Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA; et al. (2020). "Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting". Blood Rev. 41: 100648. doi:10.1016/j.blre.2019.100648. PMID 31839434.
 
 
 
 
 
 
 
 
 
 
 
 
 
History
  • Fatigue
  • Dyspnea
  • Lightheadedness

Physical examination

  • Pallor
  • Icterus
  • Cold, clammy skin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peripheral blood smear findings
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bite cells
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oxidative stress like
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment of acute attacks
  • Blood transfusion
  • Hemodialysis
  • Long term measures

    • Avoidance of trigger foods and drugs
    • Splenectomy- spleen is the site of destruction of RBCs
    • Avoid aspirin as it reduces the lifecycle of RBCs
    • Vaccination against common trigger infections such as Hepatitis A& B
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Negative
    Hereditary spherocytosis
     
     
    Positive
    • Autoantibodies
    • Alloimmunization
    • Drug-induced
    Treatment of drug induced hemolytic anemia includes removal of offending agent
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Alloimmunisation treatment

    Causes: ABO incompatible or Rh incompatible transfusion